JNJ EV/EBITDA Analysis

Trading at 18.9x, JNJ’s EV/EBITDA measures its total enterprise value relative to earnings before interest, taxes, depreciation, and amortization — a higher multiple means investors pay more for each dollar of operating profit.

This sits above the healthcare sector median of 17.9x, placing JNJ at the 100th percentile among its peers, meaning it is the most expensive stock on this basis. The metric is stable: the year-over-year change is not available, while the quarter-over-quarter change is only +0.1%, with the last three readings at 18.9x, 18.9x, and 19.0x. A high valuation that is not expanding implies the market is already pricing in consistent performance, leaving little room for upside from multiple expansion, while any operational slip would hit the stock harder than it would a cheaper peer. This combination of a premium level and a flat trend signals a lower margin of safety for new investors. The elevated multiple and lack of valuation relief support the overall CAUTIOUS verdict, as the price already reflects strong expectations with limited downside protection.

Frequently Asked Questions

Closest Sector Peers